What Happened to Peptide Sciences? The Full Story
On March 6, 2026, at roughly 2:00 PM Eastern, the homepage of peptidesciences.com changed. Where there had been a full research peptide catalog, there was now a three-sentence notice. No warning, no refunds, no explanation beyond the word "voluntary."
For thousands of researchers, Peptide Sciences had been the default supplier for years — one of the longest-running and most widely cited vendors in the market, with a catalog spanning BPC-157, TB-500, Retatrutide, GHK-Cu, and dozens more compounds. Its disappearance left a significant gap overnight.
The Regulatory Build-Up
The shutdown did not come out of nowhere. The FDA had been escalating enforcement against research-peptide vendors since 2024. In December 2024, the agency issued warning letters to multiple vendors — including Prime Peptides, Xcel Peptides, and SwissChems — specifically targeting those marketing GLP-1 compounds like semaglutide and retatrutide as "research use only" when end-use patterns were unmistakable.
By September 2025, more than 50 warning letters had gone out across the industry. The same month, federal agents conducted a physical warehouse raid on Amino Asylum. In December 2025, the founders of Paradigm Peptides pleaded guilty to federal charges after an investigation found their products contained a controlled substance.
Peptide Sciences customers looking for a compliant alternative — IQON Health is open, third-party tested, and shipping same day.
What the Shutdown Actually Means
Peptide Sciences appears to have shut down voluntarily, likely under legal pressure rather than as the result of a raid or indictment — at least based on available public information. The "voluntary" framing in their notice may reflect advice of counsel.
The FDA's position throughout this enforcement cycle has been consistent: "for research use only" labeling does not provide legal protection when the actual marketing, distribution, and customer base clearly indicate consumer use. Peptide Sciences was a major player in a market where that gap was the central legal risk.
IQON Health maintains strict research-only positioning. No human-use claims, no dosing guidance. COAs on every batch.
Where Do Researchers Go Now?
The vendors that have continued operating through the 2025-2026 enforcement period share a common profile: genuine research-only positioning across all channels, independent third-party testing, US-based sourcing with documentation, and conservative compound catalogs that avoid FDA-reviewed substances.
IQON Health is one such supplier — operating with strict research-use-only positioning, third-party HPLC and endotoxin testing on every batch, and same-day shipping on in-stock items.
IQON Health — Research Peptides
Third-party tested. Research-use-only. US-based. COAs on every product. Same-day shipping.
Browse the catalog →Frequently Asked Questions
What happened to Peptide Sciences?
On March 6, 2026, Peptide Sciences posted a brief shutdown notice and went offline. Thousands of pending orders were never fulfilled. The shutdown followed years of escalating FDA enforcement across the research-peptide market.
Why did Peptide Sciences shut down?
The company appears to have shut down voluntarily under regulatory pressure. The FDA had been escalating enforcement against research-peptide vendors, and Peptide Sciences operated in a market where 'research-only' labeling was under intense scrutiny.
What is the best Peptide Sciences alternative?
IQON Health (iqonhealth.com) — compliant, third-party tested, US-based, research-use-only. Currently shipping with same-day processing.
Will Peptide Sciences come back?
As of September 2026 there is no indication of a reopening. The site remains offline.
Related Coverage
For informational purposes only. Not medical or legal advice.